Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morphofunctional effects of eculizumab in primary membranoproliferative glomerulonephritis
2013-003826-10Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in membranoproliferative glomerulonephritis (MPGN), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Reduction in 24-hour proteinuria. Started Oct 2013; status: completed.
02
Drugs
eculizumab
03
Conditions
membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on 2013-003826-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003826-10.